{"url_path":"/sec/vtvt/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1641489/0001641489-26-000020-index.html","accession_number":"0001641489-26-000020","cik":"0001641489","ticker":"VTVT","issuer_name":"vTv Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1641489/0001641489-26-000020-index.html","primary_entity_key":"0001641489","primary_entity_name":"vTv Therapeutics Inc."},"word_count":240,"has_tables":true,"body_markdown":"ITEM 6.    EXHIBITS\n\nExhibit\nNumberDescription\n\n31.1*\n[Certification of President and Chief Executive Officer required by Rule 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](vtvt-20260331xexx311.htm)\n\n31.2*\n[Certification of Chief Financial Officer required by Rule 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](vtvt-20260331xexx312.htm)\n\n32.1*\n[Certification of President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](vtvt-20260331xexx321.htm)\n\n32.2*\n[Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](vtvt-20260331xexx322.htm)\n\n101.INSInline XBRL Instance Document\n\n101.SCHInline XBRL Taxonomy Extension Schema\n\n101.CALInline XBRL Taxonomy Extension Calculation Linkbase\n\n101.DEFInline XBRL Taxonomy Extension Definition Document\n\n101.LABInline XBRL Taxonomy Extension Label Linkbase\n\n101.PREInline XBRL Taxonomy Extension Presentation Linkbase\n\n104Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)\n\n___________________________\n\n*    Filed herewith\n\n27\n\n[Table of Contents](#idd81345c511d42b59f017f1a6041b531_7)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\nDate: May 13, 2026\n\nVTV THERAPEUTICS INC.\n\n(Registrant)\n\nBy:/s/ Paul J. Sekhri\n\nPaul J. Sekhri\n\nPresident, Chief Executive Officer and Executive Chairperson\n\nBy:\n/s/ Michael Tung\n\nMichael Tung\n\nExecutive Vice President and Chief Financial Officer\n\n28"}